electroCore (ECOR) investor relations material

Executive summary

• Achieved record quarterly revenue of $9.6 million in Q1 2026, up 43% year-over-year, driven by VA channel, Quell Fibromyalgia, and Truvaga wellness products.

• Gross margin expanded to 87%, with gross profit at $8.4 million, up from 85% and $5.7 million year-over-year.

• Leadership transition completed, with Michael Fox appointed COO, bringing federal healthcare experience.

• Net loss was $5.3 million ($0.59/share), widened from $3.9 million, due to higher operating expenses, CEO severance, and litigation costs.

• Significant customer concentration: 74.8% of revenue from the U.S. Department of Veterans Affairs.

Financial highlights

• Net sales reached $9.6 million, a 43% increase year-over-year, with $8.4 million gross profit and 87% gross margin.

• GAAP net loss was $5.3 million ($0.59/share); excluding $1.9 million in non-recurring leadership transition costs, net loss per share was $0.37.

• Adjusted EBITDA loss improved by 24% to $2.3 million, despite absorbing non-recurring expenses.

• Cash, cash equivalents, and marketable securities totaled $8.8 million at quarter-end.

• Operating expenses rose to $13.7 million, reflecting higher sales/marketing, CEO severance, and litigation costs.

Outlook and guidance

• Reaffirmed full-year 2026 revenue growth guidance of approximately 30% over 2025.

• Majority of 2026 revenue expected from VA channel, with Truvaga and Quell Relief as additional contributors.

• Company expects continued net losses in the near term as it invests in sales and marketing.

• Substantial doubt exists about ability to fund operations for the next 12 months without additional capital.

• Not yet ready to specify breakeven quarter, but trajectory toward profitability is clear.